Literature DB >> 3643793

Identification of a new tissue-kallikrein-binding protein.

J Chao, D M Tillman, M Y Wang, H S Margolius, L Chao.   

Abstract

We have identified a tissue-kallikrein-binding protein in human serum and in the serum-free culture media from human lung fibroblasts (WI-38) and rodent neuroblastoma X glioma hybrid cells (NG108-15). Purified and 125I-labelled tissue kallikrein and human serum form an approximately 92,000-Mr SDS-stable complex. The relative quantity of this complex-formation is measured by densitometric scanning of autoradiograms. Complex-formation between tissue kallikrein and the serum binding protein was time-dependent and detectable after 5 min incubation at 37 degrees C, with half-maximal binding at 28 min. Binding of 125I-kallikrein to kallikrein-binding protein is temperature-dependent and can be inhibited by heparin or excess unlabelled tissue kallikrein but not by plasma kallikrein, collagenase, thrombin, urokinase, alpha 1-antitrypsin or kininogens. The kallikrein-binding protein is acid- and heat-labile, as pretreatment of sera at pH 3.0 or at 60 degrees C for 30 min diminishes complex-formation. However, the formed complexes are stable to acid or 1 M-hydroxylamine treatment and can only be partially dissociated with 10 mM-NaOH. When kallikrein was inhibited by the active-site-labelling reagents phenylmethanesulphonyl fluoride or D-Phe-D-Phe-L-Arg-CH2Cl no complex-formation was observed. An endogenous approximately 92,000-Mr kallikrein-kallikrein-binding protein complex was isolated from normal human serum by using a human tissue kallikrein-agarose affinity column. These complexes were recognized by anti-(human tissue kallikrein) antibodies, but not by anti-alpha 1-antitrypsin serum, in Western-blot analyses. The results show that the kallikrein-binding protein is distinct from alpha 1-antitrypsin and is not identifiable with any of the well-characterized plasma proteinase inhibitors such as alpha 2-macroglobulin, inter-alpha-trypsin inhibitor, C1-inactivator or antithrombin III. The functional role of this kallikrein-binding protein and its impact on kallikrein activity or metabolism in vivo remain to be investigated.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3643793      PMCID: PMC1147284          DOI: 10.1042/bj2390325

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  20 in total

1.  Purification and characterization of tonin.

Authors:  S Cemassieux; R Boucher; C Crisé; J Genest
Journal:  Can J Biochem       Date:  1976-09

2.  "Western blotting": electrophoretic transfer of proteins from sodium dodecyl sulfate--polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A.

Authors:  W N Burnette
Journal:  Anal Biochem       Date:  1981-04       Impact factor: 3.365

3.  Characterization and origin of immunoreactive glandular kallikrein in rat plasma.

Authors:  W J Lawton; D Proud; M E Frech; J V Pierce; H R Keiser; J J Pisano
Journal:  Biochem Pharmacol       Date:  1981-07-01       Impact factor: 5.858

4.  The radioimmunoassay of human urinary kallikrein and comparisons with kallikrein activity measurements.

Authors:  K Shimamoto; J Chao; H S Margolius
Journal:  J Clin Endocrinol Metab       Date:  1980-10       Impact factor: 5.958

5.  Evidence that a variety of cultured cells secrete protease nexin and produce a distinct cytoplasmic serine protease-binding factor.

Authors:  D L Eaton; J B Baker
Journal:  J Cell Physiol       Date:  1983-11       Impact factor: 6.384

6.  Alpha 1-antitrypsin and alpha 2-macroglobulin do not inhibit the kinin-releasing activity of kallikreins from human urine and saliva.

Authors:  W Sakamoto; O Nishikaze
Journal:  Biochim Biophys Acta       Date:  1980-12-15

7.  Purification of human protease nexin.

Authors:  R W Scott; J B Baker
Journal:  J Biol Chem       Date:  1983-09-10       Impact factor: 5.157

8.  Purification and characterization of rat urinary esterase A, a plasminogen activator.

Authors:  J Chao
Journal:  J Biol Chem       Date:  1983-04-10       Impact factor: 5.157

9.  Protease-nexin: a cellular component that links thrombin and plasminogen activator and mediates their binding to cells.

Authors:  J B Baker; D A Low; R L Simmer; D D Cunningham
Journal:  Cell       Date:  1980-08       Impact factor: 41.582

10.  Absence of binding of pancreatic and urinary kallikreins to alpha 2-macroglobulin.

Authors:  E Vahtera; U Hamberg
Journal:  Biochem J       Date:  1976-08-01       Impact factor: 3.857

View more
  29 in total

Review 1.  Wnt pathway antagonists and angiogenesis.

Authors:  Bin Zhang; Jian-Xing Ma
Journal:  Protein Cell       Date:  2010-11-09       Impact factor: 14.870

Review 2.  Protective Role of Kallistatin in Vascular and Organ Injury.

Authors:  Julie Chao; Grant Bledsoe; Lee Chao
Journal:  Hypertension       Date:  2016-07-18       Impact factor: 10.190

Review 3.  Angiogenesis in diabetes and obesity.

Authors:  Rui Cheng; Jian-xing Ma
Journal:  Rev Endocr Metab Disord       Date:  2015-03       Impact factor: 6.514

4.  Blocking the Wnt pathway, a unifying mechanism for an angiogenic inhibitor in the serine proteinase inhibitor family.

Authors:  Bin Zhang; Jose G Abreu; Kevin Zhou; Ying Chen; Yang Hu; Ti Zhou; Xi He; Jian-xing Ma
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-29       Impact factor: 11.205

Review 5.  Kallistatin suppresses cancer development by multi-factorial actions.

Authors:  Julie Chao; Pengfei Li; Lee Chao
Journal:  Crit Rev Oncol Hematol       Date:  2017-03-14       Impact factor: 6.312

6.  Differential interactions of human kallikrein-binding protein and alpha 1-antitrypsin with human tissue kallikrein.

Authors:  L M Chen; L Chao; R K Mayfield; J Chao
Journal:  Biochem J       Date:  1990-04-01       Impact factor: 3.857

7.  Kallistatin ameliorates influenza virus pathogenesis by inhibition of kallikrein-related peptidase 1-mediated cleavage of viral hemagglutinin.

Authors:  Chia-Hsing Leu; Mei-Lin Yang; Nai-Hui Chung; Yen-Jang Huang; Yu-Chu Su; Yi-Cheng Chen; Chia-Cheng Lin; Gia-Shing Shieh; Meng-Ya Chang; Shainn-Wei Wang; Yao Chang; Julie Chao; Lee Chao; Chao-Liang Wu; Ai-Li Shiau
Journal:  Antimicrob Agents Chemother       Date:  2015-07-06       Impact factor: 5.191

8.  Human kallistatin administration reduces organ injury and improves survival in a mouse model of polymicrobial sepsis.

Authors:  Pengfei Li; Grant Bledsoe; Zhi-Rong Yang; Hongkuan Fan; Lee Chao; Julie Chao
Journal:  Immunology       Date:  2014-06       Impact factor: 7.397

9.  Inhibition of connective tissue growth factor overexpression in diabetic retinopathy by SERPINA3K via blocking the WNT/beta-catenin pathway.

Authors:  Bin Zhang; Kevin K Zhou; Jian-xing Ma
Journal:  Diabetes       Date:  2010-03-18       Impact factor: 9.461

10.  SERPINA3K prevents oxidative stress induced necrotic cell death by inhibiting calcium overload.

Authors:  Bin Zhang; Jian-xing Ma
Journal:  PLoS One       Date:  2008-12-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.